"Volix" Regain The Pride
Volix (Voglibose) by Ranbaxy CV Care comes in .2 mg and .3 mg in form of tablets
Volix (Voglibose) is an anti-diabetic agent that improves postprandial hyperglycemia. It acts by delaying the digestion and absorption of sugar. Volix (Voglibose), marketed in
Volix (Voglibose) is an inhibitor of alpha-glucosidase with general properties similar to those of acarbose. Volix (Voglibose) has been investigated 1 in the management of hepatic encephalopathy.
Volix (Voglibose) is slowly and poorly absorbed, and is rapidly excreted. Little metabolism occurs and no metabolites have as yet been ...Volix (Voglibose) competitively and reversibly inhibits the alpha–glucosidase enzymes; glucoamylase, sucrase, etc
Volix (Voglibose) should be administered in conjunction with diet treatment or diet plus a sulfonylurea. ... Some investigators recommend the
Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.
There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest. Voglibose scores over both acarbose and miglitol in terms of side effect profile. But acarbose has an edge over voglibose in terms of efficacy (FPG, PPHG, HBA1c).
There are several trials supporting the use of voglibose in the management of PPHG. Also, it has been established that it is PPHG, not FPG, which is the marker of cardiovascular disorders associated with diabetes. So, controlling PPHG is imperative and voglibose is indicated for the management of PPHG.
Volix Ranbaxy CV Care - General Information:
Volix (Ranbaxy labs) (INN and USAN) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix. [Wikipedia]
Volix (Ranbaxy labs), an alpha-glucosidase inhibitor, is a synthetic compound with potent and enduring therapeutic efficacies against disorders of sensory, motor and autonomic nerve systems due to diabetes mellitus. The drug was approved in Japan in 1994 for the treatment of diabetes, and it is under further investigation by Takeda for the treatment of impaired glucose tolerance. Alpha-glucosidase inhibitors are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of complex carbohydrates (such as starch). Complex carbohydrates are normally converted into simple sugars (monosaccharides) which can be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of complex carbohydrates on blood sugar.